Company News
14 June 2024
Investor Q&A with Steven Yatomi-Clarke
In this session Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke discussed the key highlights:
- An update on Prescient’s strategy and upcoming milestones, with a focus on PTX-100.
- The journey of value creation for biotech companies, and why Prescient is on the cusp of a significant inflection point.
- Why the data from their PTX-100 Phase 1b trial is so promising.
- How the development pathway for PTX-100 could be considerably shorter and cheaper than conventional drug development paths.
- How their $18m cash position allows them to go deep into a Phase 2 trial.
Recorded on 25th March 2024 at 12pm (AEDT).
Company News
View all
Open investments
View all
Copper Bay Resources
Request Offer Docs
Investment Type:
Our Role:
Wellnex Life Limited Shortfall Placement
Request Offer Docs Investment Type:
Our Role:
Red Piranha
Request Offer Docs
Amount Raised:
Investment Type:
Our Role:
upcoming events
View all
Connecting quality investors and innovative companies to facilitate mutual wealth creation with trust and transparency
Speak to an Adviser
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.